EGFR and cancer: Similar to targeted therapies that tackle a gain-of-function in cancer, such as EGFR inhibitors, the introduction of the antagonist specific to oncomiRNA miR-335 interferes with the oncogenic properties of astrocytoma cells and induces therapeutic responses.